[Cellular immunity in human brain tumours (author's transl)]

Area of Science:

• Immunology
• Neuro-oncology
• Tumor immunology

Context:

• Intracranial tumors represent a significant challenge in neuro-oncology.
• Understanding cellular immunity to autologous tumors is crucial for developing effective treatments.
• Previous studies have explored immune responses in various cancers, but specific data on intracranial tumors remain limited.

Purpose:

• To evaluate cellular immunity in patients with diverse intracranial tumors using two distinct immunological assays.
• To compare the sensitivity of the Leucocyte Migration Inhibition Technique (LMI) and intracutaneous testing for detecting tumor-specific cellular immunity.
• To determine the prevalence of cellular immunity across different types of intracranial tumors, including malignant gliomas, slow-growing gliomas, brain sarcomas, and meningiomas.

Summary:

• Forty-four patients with intracranial tumors underwent assessment of cellular immunity via Leucocyte Migration Inhibition (LMI) and intracutaneous testing.
• A strong correlation was observed between the two methods, with LMI demonstrating higher sensitivity.
• Cellular immunity was detected in 3/18 malignant gliomas, 6/16 slow-growing gliomas, 5/6 brain sarcomas, and 1/4 meningiomas.

Impact:

• This study highlights the utility of LMI as a sensitive tool for assessing cellular immunity in neuro-oncology.
• Findings provide insights into the varying degrees of cellular immune response across different intracranial tumor types.
• Results may inform the development of immunotherapeutic strategies tailored to specific brain tumor pathologies.